{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T06:17:59Z","timestamp":1778221079639,"version":"3.51.4"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:00:00Z","timestamp":1778198400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Immune checkpoint inhibitors (ICIs) provide durable benefit for a subset of patients with advanced non-small cell lung cancer (NSCLC), however predictive biomarkers remain limited. Peripheral blood offers accessible immune and inflammatory signals that may reflect the onset of systemic mechanisms of resistance. This study aimed to identify circulating immune features associated with clinical outcome and to develop a clinically applicable blood-based score for risk stratification in patients receiving ICIs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Two independent real-world cohorts of advanced NSCLC patients treated with anti-PD-1 therapy were analyzed. Plasma cytokines and chemokines, soluble immune checkpoint molecules and blood cell counts were measured before and during ICI-therapy. Baseline biomarkers associated with progression-free survival (PFS) and overall survival (OS) were incorporated into an Immune-Suppressive Blood Index Score (ISBIS). The ISBIS discriminative performance was first determined in the discovery cohort (n=57) and then validated in an independent cohort (n=56), and nomogram integrating ISBIS with clinical variables was generated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>ISBIS score predicts poor outcome to be associated with an immunosuppressive blood profile composed of baseline IL-6, IL-8, CCL2, CXCL10, neutrophils, PLR, IFN-\u03b3 and lymphocytes. On-treatment increase in CXCL10, neutrophils, and NLR, as well as decreases in lymphocytes and soluble PD-L2, were associated with early disease progression. ISBIS stratified patients into three risk groups with significantly different survival in both cohorts and remained independently associated to OS. A nomogram combining ISBIS with ECOG-PS (Eastern Cooperative Oncology Group - Performance Status), disease burden, sex, and NLR (neutrophil-to-lymphocyte ratio) demonstrated strong discrimination and validated accuracy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>A systemic immune-suppressive profile identifies patients with poor outcomes to ICIs. ISBIS integrates critical immune and inflammatory signals into a clinically applicable tool, supporting personalized immunotherapy strategies in advanced NSCLC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1772319","type":"journal-article","created":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T05:51:47Z","timestamp":1778219507000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["A blood-based immune-suppressive index stratifies immunotherapy outcomes in advanced NSCLC"],"prefix":"10.3389","volume":"17","author":[{"given":"Luca","family":"Lalli","sequence":"first","affiliation":[{"name":"Translational Immunology Unit, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori","place":["Milan, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veronica","family":"Huber","sequence":"additional","affiliation":[{"name":"Translational Immunology Unit, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori","place":["Milan, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agata","family":"Cova","sequence":"additional","affiliation":[{"name":"Translational Immunology Unit, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori","place":["Milan, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Daveri","sequence":"additional","affiliation":[{"name":"Translational Immunology Unit, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori","place":["Milan, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"List\u00ec","sequence":"additional","affiliation":[{"name":"Department of Oncology, University of Turin, S. Luigi Gonzaga Hospital-Orbassano","place":["Turin, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Rossi","sequence":"additional","affiliation":[{"name":"UOC Oncologia Medica, IRCCS Azienda Ospedaliera Metropolitana (IRCCS AOM), Plesso: Ospedale Policlinico San Martino","place":["Genoa, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo","family":"Genova","sequence":"additional","affiliation":[{"name":"UOC Oncologia Medica, IRCCS Azienda Ospedaliera Metropolitana (IRCCS AOM), Plesso: Ospedale Policlinico San Martino","place":["Genoa, Italy"]},{"name":"Dipartimento Di Medicina Interna E Specialit\u00e0 Mediche (DiMI), Universit\u00e0 Degli Studi Di Genova","place":["Genoa, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simona","family":"Coco","sequence":"additional","affiliation":[{"name":"UOC Oncologia Medica, IRCCS Azienda Ospedaliera Metropolitana (IRCCS AOM), Plesso: Ospedale Policlinico San Martino","place":["Genoa, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iosune","family":"Baraibar","sequence":"additional","affiliation":[{"name":"Department of Oncology, Cl\u00ednica Universidad de Navarra","place":["Pamplona, Spain"]},{"name":"Program in Solid Tumors, Center for Applied Medical Research and Navarra Institute for Health Research","place":["Pamplona, Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ignacio","family":"Gil-Bazo","sequence":"additional","affiliation":[{"name":"Department of Oncology, Cl\u00ednica Universidad de Navarra","place":["Pamplona, Spain"]},{"name":"Program in Solid Tumors, Center for Applied Medical Research and Navarra Institute for Health Research","place":["Pamplona, Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Novello","sequence":"additional","affiliation":[{"name":"Department of Oncology, University of Turin, S. Luigi Gonzaga Hospital-Orbassano","place":["Turin, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Licia","family":"Rivoltini","sequence":"additional","affiliation":[{"name":"Translational Immunology Unit, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori","place":["Milan, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Passiglia","sequence":"additional","affiliation":[{"name":"Department of Oncology, University of Turin, S. Luigi Gonzaga Hospital-Orbassano","place":["Turin, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.00174","article-title":"Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non\u2013small-cell lung cancer with PD-L1 tumor proportion score \u2265 50%","volume":"39","author":"Reck","year":"2021","journal-title":"JCO"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1200\/jco.20.01605","article-title":"Five-year outcomes from the randomized, phase III trials CheckMate 017 and 057: Nivolumab versus docetaxel in previously treated non-small-cell lung cancer","volume":"39","author":"Borghaei","year":"2021","journal-title":"J Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.05.001","article-title":"Five year survival update from KEYNOTE-010: Pembrolizumab versus docetaxel for previously treated, programmed death-ligand 1-positive advanced NSCLC","volume":"16","author":"Herbst","year":"2021","journal-title":"J Thorac Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.09.022","article-title":"Atezolizumab versus docetaxel in pretreated patients with NSCLC: Final results from the randomized phase 2 POPLAR and phase 3 OAK clinical trials","volume":"16","author":"Mazieres","year":"2021","journal-title":"J Thorac Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1200\/jco.22.01989","article-title":"Pembrolizumab plus pemetrexed and platinum in nonsquamous non-small-cell lung cancer: 5-year outcomes from the phase 3 KEYNOTE-189 study","volume":"41","author":"Garassino","year":"2023","journal-title":"J Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1200\/jco.22.01990","article-title":"Pembrolizumab plus chemotherapy in squamous non-small-cell lung cancer: 5-year update of the phase III KEYNOTE-407 study","volume":"41","author":"Novello","year":"2023","journal-title":"J Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.114296","article-title":"Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus 4 cycles of chemotherapy alone in patients with metastatic non-small cell lung cancer in the randomized CheckMate 9LA trial","volume":"211","author":"Reck","year":"2024","journal-title":"Eur J Cancer"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-025-01061-7","article-title":"Treatment of NSCLC after chemoimmunotherapy - are we making headway","volume":"22","author":"Reck","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"2626","DOI":"10.3390\/cancers14112626","article-title":"Emerging blood-based biomarkers for predicting immunotherapy response in NSCLC","volume":"14","author":"Oitab\u00e9n","year":"2022","journal-title":"Cancers"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dju124","article-title":"Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis","volume":"106","author":"Templeton","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.lungcan.2017.01.013","article-title":"Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer","volume":"106","author":"Bagley","year":"2017","journal-title":"Lung Cancer"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2017.07.024","article-title":"Neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab","volume":"111","author":"Diem","year":"2017","journal-title":"Lung Cancer"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw016","article-title":"Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab","volume":"27","author":"Ferrucci","year":"2016","journal-title":"Ann Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s10238-025-01587-1","article-title":"Predictive value of serum cytokines in patients with non-small-cell lung cancer receiving anti-PD-1 blockade therapy: a meta-analysis","volume":"25","author":"Liu","year":"2025","journal-title":"Clin Exp Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1430301","article-title":"Prognostic role of serum cytokines level in non-small cell lung cancer patients with anti-PD-1 and chemotherapy combined treatment","volume":"15","author":"Liu","year":"2024","journal-title":"Front Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000678","article-title":"Plasma IL-6 changes correlate to PD-1 inhibitor responses in NSCLC","volume":"8","author":"Keegan","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B17","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1186\/s12916-022-02356-7","article-title":"Systematic analysis of IL-6 as a predictive biomarker and desensitizer of immunotherapy responses in patients with non-small cell lung cancer","volume":"20","author":"Liu","year":"2022","journal-title":"BMC Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx190","article-title":"Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients","volume":"28","author":"Sanmamed","year":"2017","journal-title":"Ann Oncol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s12672-023-00641-2","article-title":"Association between response to anti-PD-1 treatment and blood soluble PD-L1 and IL-8 changes in patients with NSCLC","volume":"14","author":"Yi","year":"2023","journal-title":"Discov Onc"},{"key":"B20","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1007\/s00262-024-03781-8","article-title":"Characterization of pre- and on-treatment soluble immune mediators and the tumor microenvironment in NSCLC patients receiving PD-1\/L1 inhibitor monotherapy","volume":"73","author":"Murata","year":"2024","journal-title":"Cancer Immunol Immunother"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.5918","article-title":"Distinct circulating cytokine\/chemokine profiles correlate with clinical benefit of immune checkpoint inhibitor monotherapy and combination therapy in advanced non-small cell lung cancer","volume":"12","author":"Hu","year":"2023","journal-title":"Cancer Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1172\/JCI91190","article-title":"IFN-\u03b3-related mRNA profile predicts clinical response to PD-1 blockade","volume":"127","author":"Ayers","year":"2017","journal-title":"J Clin Invest"},{"key":"B23","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s40001-024-01711-z","article-title":"The paradoxical role of cytokines and chemokines at the tumor microenvironment: a comprehensive review","volume":"29","author":"Abdul-Rahman","year":"2024","journal-title":"Eur J Med Res"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2017.49","article-title":"Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy","volume":"17","author":"Nagarsheth","year":"2017","journal-title":"Nat Rev Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10102534","article-title":"Robust preanalytical performance of soluble PD-1, PD-L1 and PD-L2 assessed by sensitive ELISAs in blood","volume":"10","author":"Krueger","year":"2022","journal-title":"Biomedicines"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1002\/jcla.70153","article-title":"Matrix type influences the levels of soluble immune checkpoints","volume":"40","author":"Buia","year":"2026","journal-title":"J Clin Lab Anal"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.887916","article-title":"Soluble immune checkpoint-related proteins in blood are associated with invasion and progression in non-small cell lung cancer","volume":"13","author":"Wang","year":"2022","journal-title":"Front Immunol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1177\/03936155231226234","article-title":"Cytokine and soluble programmed death-ligand 1 levels in serum and plasma of cancer patients treated with immunotherapy: Preanalytical and analytical considerations","volume":"39","author":"Cappelletto","year":"2024","journal-title":"Int J Biol Markers"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4466","article-title":"High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy","volume":"24","author":"Krieg","year":"2018","journal-title":"Nat Med"},{"key":"B30","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1186\/s12935-024-03412-3","article-title":"Blood-based molecular and cellular biomarkers of early response to neoadjuvant PD-1 blockade in patients with non-small cell lung cancer","volume":"24","author":"Zhang","year":"2024","journal-title":"Cancer Cell Int"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007530","article-title":"New perspectives in cancer immunotherapy: targeting IL-6 cytokine family","volume":"11","author":"Soler","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B32","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1186\/s40425-019-0706-x","article-title":"Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors","volume":"7","author":"Bilusic","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25126532","article-title":"Chemokines and cytokines in immunotherapy of melanoma and other tumors: From biomarkers to therapeutic targets","volume":"25","author":"Reschke","year":"2024","journal-title":"IJMS"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2025.102978","article-title":"Immunocytokines in cancer treatment: A systematic review","volume":"139","author":"Agliardi","year":"2025","journal-title":"Cancer Treat Rev"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/S2589-7500(23)00082-1","article-title":"Predicting benefit from immune checkpoint inhibitors in patients with non-small-cell lung cancer by CT-based ensemble deep learning: a retrospective study","volume":"5","author":"Saad","year":"2023","journal-title":"Lancet Digit Health"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1093\/jamia\/ocaf074","article-title":"Multimodal integration of longitudinal noninvasive diagnostics for survival prediction in immunotherapy using deep learning","volume":"32","author":"Yeghaian","year":"2025","journal-title":"J Am Med Inform Assoc"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1772319\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T05:51:48Z","timestamp":1778219508000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1772319\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,8]]},"references-count":36,"alternative-id":["10.3389\/fimmu.2026.1772319"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1772319","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,8]]},"article-number":"1772319"}}